Search Results - "Incerti, Devin"

Short-term costs of preeclampsia to the United States health care system by Stevens, Warren, Shih, Tiffany, Incerti, Devin, Ton, Thanh G.N., Lee, Henry C., Peneva, Desi, Macones, George A., Sibai, Baha M., Jena, Anupam B.

“…Preeclampsia is a leading cause of maternal morbidity and mortality and adverse neonatal outcomes. Little is known about the extent of the health and cost…”
Get full text

Prognostic model to identify and quantify risk factors for mortality among hospitalised patients with COVID-19 in the USA by Incerti, Devin, Rizzo, Shemra, Li, Xiao, Lindsay, Lisa, Yau, Vincent, Keebler, Dan, Chia, Jenny, Tsai, Larry

“…ObjectivesTo develop a prognostic model to identify and quantify risk factors for mortality among patients admitted to the hospital with…”
Get full text

Retrospective cohort study to assess the association between treatment with tocilizumab and mortality among mechanically ventilated patients with COVID-19 by Skarbinski, Jacek, Liu, Liyan, Hong, Vennis, Amsden, Laura B, Fireman, Bruce H, Yau, Vincent M, Incerti, Devin, Qian, Lei, Fischer, Heidi, Ackerson, Bradley K, Shaw, Sally F, Tartof, Sara Y

“…ObjectivesAssess the association between tocilizumab administration and clinical outcomes among mechanically ventilated patients with COVID-19…”
Get full text

An empirical tool for estimating the share of unmet need due to healthcare inefficiencies, suboptimal access, and lack of effective technologies by Incerti, Devin, Browne, John, Huber, Caroline, Baker, Christine L, Makinson, Geoff, Goren, Amir, Willke, Richard, Stevens, Warren

“…Although there has been growing attention to the measurement of unmet need, which is the overall epidemiological burden of disease, current measures ignore the…”
Get full text

The Lifetime Health Burden of Delayed Graft Function in Kidney Transplant Recipients in the United States by Incerti, Devin, Summers, Nicholas, Ton, Thanh G. N., Boscoe, Audra, Chandraker, Anil, Stevens, Warren

“…Background. Although delayed graft function (DGF) is associated with an increased risk of acute rejection and decreased graft survival, there are no estimates…”
Get full text

The optimal allocation of campaign funds in U.S. House elections by Incerti, Devin

“…How should political parties allocate resources in U.S. House elections? Are actual spending strategies optimal? This paper answers these questions by using…”
Get full text

Penalized regression for left‐truncated and right‐censored survival data by McGough, Sarah F., Incerti, Devin, Lyalina, Svetlana, Copping, Ryan, Narasimhan, Balasubramanian, Tibshirani, Robert

“…High‐dimensional data are becoming increasingly common in the medical field as large volumes of patient information are collected and processed by…”
Get full text

R You Still Using Excel? The Advantages of Modern Software Tools for Health Technology Assessment by Incerti, Devin, Thom, Howard, Baio, Gianluca, Jansen, Jeroen P.

“…Economic models are used in health technology assessments (HTAs) to evaluate the cost-effectiveness of competing medical technologies and inform the efficient…”
Get full text

Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project by Jansen, Jeroen P., Incerti, Devin, Linthicum, Mark T.

“…The Innovation and Value Initiative started the Open-Source Value Project with the aim to improve the credibility and relevance of model-based value assessment…”
Get full text

Cost-effectiveness of genome sequencing for diagnosing patients with undiagnosed rare genetic diseases by Incerti, Devin, Xu, Xiang-Ming, Chou, Jacquelyn W., Gonzaludo, Nina, Belmont, John W., Schroeder, Brock E.

“…To estimate the cost-effectiveness of genome sequencing (GS) for diagnosing critically ill infants and noncritically ill pediatric patients (children) with…”
Get full text

Multi‐state network meta‐analysis of progression and survival data by Jansen, Jeroen P., Incerti, Devin, Trikalinos, Thomas A.

“…Summary Multiple randomized controlled trials, each comparing a subset of competing interventions, can be synthesized by means of a network meta‐analysis to…”
Get full text

Abstract PS10-20: Neoadjuvant (neoadj) and adjuvant (adj) treatment patterns in HER2-positive early breast cancer (EBC): Analysis of US real-world oncology data by Dhillon, Preet K., Flores, Carlos, Sanglier, Thibaut, Antao, Vincent, Tesarowski, David, Fung, Anita, Incerti, Devin, Restuccia, Eleonora, Luhn, Patricia

“…Abstract OBJECTIVES Over the last decade, new treatment options have transformed the standard of care for patients (pts) with HER2-positive EBC and the…”
Get full text

Temporal Patterns and Adoption of Germline and Somatic BRCA Testing in Ovarian Cancer by Huepenbecker, Sarah P., Wright, Jason D., Downer, Mary K., Incerti, Devin, Luhn, Patricia, Dolado, Ignacio, Bastiere-Truchot, Lydie, Lin, Yvonne G., Chan, John K., Meyer, Larissa A.

Get full text

Temporal Patterns and Adoption of Germline and Somatic BRCA Testing in Ovarian Cancer in a Real-World Database by Huepenbecker, Sarah P., Wright, Jason D., Downer, Mary K., Incerti, Devin, Luhn, Patricia, Dolado, Ignacio, Bastiere-Truchot, Lydie, Lin, Yvonne G., Chan, John K., Meyer, Larissa A.

“…In a large cohort of patients with ovarian cancer, testing for germline and somatic BRCA mutations has increased over time, but significant practice…”
Get full text

An empirical investigation of time‐varying cost‐effectiveness across the product life cycle by Stevens, Warren, Incerti, Devin, Peneva, Desi, Shrestha, Anshu, Smith, Gregory, Ramaswamy, Krishnan

“…ABSTRACT Cost‐effectiveness is traditionally treated as a static estimate driven by clinical trial efficacy and drug price at launch. Prior studies suggest…”
Get full text

Left truncation in linked data: A practical guide to understanding left truncation and applying it using SAS and R by Jin, Yanling, Ton, Thanh G. N., Incerti, Devin, Hu, Sylvia

“…Time‐to‐event data such as time to death are broadly used in medical research and drug development to understand the efficacy of a therapeutic. For…”
Get full text

A meta‐analytic framework to adjust for bias in external control studies by Incerti, Devin, Bretscher, Michael T., Lin, Ray, Harbron, Chris

“…While randomized controlled trials (RCTs) are the gold standard for estimating treatment effects in medical research, there is increasing use of and interest…”
Get full text

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants by Shahabi, Ahva, Peneva, Desi, Incerti, Devin, McLaurin, Kimmie, Stevens, Warren

“…Background The variability in cost of palivizumab treatment, indicated for prevention of respiratory syncytial virus (RSV) infections in high-risk infants, has…”
Get full text

Real‐World Evidence to Supplement Randomized Clinical Trials: Tocilizumab for Severe COVID‐19 Pneumonia vs. a Cohort Receiving Standard of Care by Skarbinski, Jacek, Fischer, Heidi, Hong, Vennis, Liu, Liyan, Yau, Vincent M., Incerti, Devin, Qian, Lei, Ackerson, Bradley K., Amsden, Laura B., Shaw, Sally F., Tartof, Sara Y.

“…Randomized controlled trials (RCTs) remain the gold standard for evaluating treatment efficacy, but real‐world evidence can supplement RCT results. Tocilizumab…”
Get full text

A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis by Incerti, Devin, Curtis, Jeffrey R., Shafrin, Jason, Lakdawalla, Darius N., Jansen, Jeroen P.

“…Objective The nature of model-based cost-effectiveness analysis can lead to disputes in the scientific community. We propose an iterative and collaborative…”
Get full text